ASH Clinical News November 2015 | Page 7

VOLUME 01 | NUMBER 11 | NOVEMBER 2015 Around the Network IN THIS ISSUE AMERICAN SOCIETY OF HEMATOLOGY HEADQUARTERS 2021 L Street NW, Suite 900 Washington, DC 20036 www.hematology.org Tel: [phone] on location 15th International Myeloma Workshop EDITOR-IN-CHIEF Mikkael Sekeres, MD, MS Myeloma specialists from around the world gathered in Rome, Italy, to discuss advances in the biology and treatment of multiple myeloma. Here, we share some of the research highlights from the meeting, including the benefit of autologous transplantation with carfilzomib, a pooled analysis of maintenance therapy in myeloma, and an early study of marizomib in relapsed/refractory disease. ASSOCIATE EDITORS 46 Vice-Chair for Clinical Research Director, Leukemia Program Cleveland Clinic, Taussig Cancer Institute Cleveland, OH Beth Faiman, CNP, PhD Cleveland Clinic Cleveland, OH Alice Ma, MD University of North Carolina School of Medicine Chapel Hill, NC David Steensma, MD Dana-Farber Cancer Institute Boston, MA Keith Stewart, MBChB, MBA Mayo Clinic Scottsdale, AZ PUBLISHER American Medical Communications EDITORIAL MANAGING EDITORS Ariel Jones-DeMaio, AMC Karen Learner, ASH ART DIRECTOR Ari Mihos ASSISTANT ART DIRECTOR Charlene DePrizio DIGITAL PROJECTS MANAGER Chris Gedikli ADVERTISING ACCOUNT MANAGER Nick Luciano [email protected] Gene Conselyea [email protected] Recruitment advertising orders can be sent to: DIRECTOR, RECRUITMENT CLASSIFIEDS Lauren Morgan [email protected] Visit us at ashclinicalnews.org Follow us on Twitter @ASHClinicalNews ©2015 by the American Society of Hematology. All materials contained in this newsletter are protected by copyright laws and may not be used, reproduced, or otherwise exploited in any manner without the express prior written permission of ASH Clinical News. Any third-party materials communicated to ASH Clinical News become its copyrighted property and may be used, reproduced, or otherwise exploited by ASH Clinical News. ASHClinicalNews.org Adapting to Conference Climate Change Presenting research at a scientific meeting in 2015 is vastly different than it was even 10 years ago. Information presented at major medical meetings is often instantly public, and that immediacy has far-reaching implications for how presenters choose to share their information. We take a look at this rapidly changing environment and how researchers, clinicians, and meeting organizers are working to adapt. clinical news 34 Practice Update: New Medicare Care Choices Model Seeks to Expand Access to Palliative Care 35 Study Finds Link Between Non-Hodgkin Lymphoma and Coxiella Burnetii Infection 54 You Make the Call: Tranexamic Acid for Pre- and Peri-Operative Anticoagulation 57 ASHCLINICALNEWS.ORG Are you ready for the 57th ASH Annual Meeting & Exposition? ASH Clinical News is here to help! If you’re presenting at the meeting, brush up on your presentation skills with these tips: “The Do’s and Don’ts of Research Presentations” by Morie A. Gertz, MD (ashclinicalnews.org/the-dos-anddonts-of-research-presentations) If you’re ready to embrace social media, read how one doctor was converted: Check us out on Twitter for onsite updates from the annual meeting: @ASHClinicalNews Follow the conversation by searching #ASH15 You can also sign up to receive our “On Location” e-newsletters to have the latest annual meeting news delivered to your inbox: ashclinicalnews.org/ enewsletter-sign-up “@BldCancerDoc, Or How I Learned to Stop Worrying and Love Twitter” by Navneet Majhail, MD (ashclinicalnews. org/bldcancerdoc-or-how-i-learnedto-stop-worrying-and-love-twitter) Subscription inquiries should be sent to: [email protected] All correspondence for the American Society of Hematology should be sent to: American Society of Hematology, 2021 L Street NW, Suite 900, Washington DC 20036. Neither the American Society of Hematology nor the publisher is responsible for statements made by any editor or contributor. Statements, editorials, or opinions expressed in ASH Clinical News magazine do not necessarily represent official policy of the American Society of Hematology unless so state B